PRESTIGE CONSUMER HEALTHCARE INC. (PBH): what the price assumes

boothcheck covers PRESTIGE CONSUMER HEALTHCARE INC. (PBH) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-06-28.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/PBH

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 4.6% sits below it).

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Earnings, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.9%); the inversion above states its own rate.

Per-Model Detail (n=13)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Prestige owns a portfolio of niche over-the-counter consumer health brands at a 28% operating margin, the economics of category leaders that need little reinvestment and throw off steady cash.
• The cash funds an acquisition machine: the company is buying the Breathe Right nasal-strip brand and Australia's LaCorium skin-care business, financed with new term debt that lifts leverage before cash flow brings it back down.
• The structural worry is organic decline, full-year revenue fell about 4%, so the next read is whether the guided return to 1% to 3% organic growth in fiscal 2027 actually arrives or the company keeps buying growth it cannot generate internally.

Bull Case

The asset worth owning here is the balance sheet's ability to keep buying brands and paying for them out of cash flow. Prestige runs a collection of category-leading over-the-counter health brands at a 28% operating margin, and the model is built on the fact that established consumer-health brands need modest advertising and little capital to maintain. The company's stated strategy is exactly that: develop existing brands through new lines and advertising, and add to the portfolio through acquisition "We develop our existing brands by investing in new product lines, brand extensions and strong advertising support. Acquisitions of consumer health and personal care brands have als". That generates roughly $246 million of free cash flow against a manageable debt load, the fuel for the acquisition engine.

That engine is running. The company is acquiring the Breathe Right nasal-strip brand, a category leader, and Australia's LaCorium therapeutic skin-care business for about $150 million, with LaCorium adding roughly $40 million of revenue and about $12 million of EBITDA including synergies. These are the kind of deals Prestige has done well historically: buy a defensible niche brand, plug it into an existing distribution and marketing machine, and let the margin flow through. The deals are debt-financed, which lifts leverage in the near term, but the playbook is to deleverage afterward using the strong cash flow the portfolio generates.

Capital return rounds out the picture. The company recently completed a $207 million buyback, retiring more than 6% of its shares, and the share count has been falling. For a business with steady margins and reliable cash conversion, retiring shares at a blended earnings multiple in the high teens compounds value for the holders who stay. The bull case is a cash-generative brand portfolio whose balance sheet can keep absorbing accretive niche acquisitions while returning capital, with the leverage taken on for Breathe Right and LaCorium the kind the cash flow has historically paid down.

Bear Case

The structural truth a Prestige holder has to sit with is that the existing portfolio is not growing on its own. Full-year fiscal 2026 revenue fell about 4%, and the fourth quarter declined 5% on weaker eye-and-ear-care sales and Middle East shipping disruptions. A brands business whose organic top line shrinks is, by definition, leaning on price increases and acquisitions to stand still. Management is guiding to a return to 1% to 3% organic growth in fiscal 2027, but that is a forecast of recovery from decline, not evidence of it, and roughly a third of even that modest growth is expected to come from pricing rather than volume. The bet the price makes on a value-supported, durable portfolio assumes the brands hold their shelf position; the recent numbers show that holding it is getting harder.

That dependence on acquired growth is the second concern, and it changes the risk profile. The Breathe Right and LaCorium deals are financed with new term loan debt, which pushes leverage higher before the deleveraging begins. An acquisition strategy works only as long as accretive niche brands are available at sensible prices and the balance sheet can carry the deals; in a higher-rate environment, the cost of that debt is real, and a string of acquisitions to offset organic decline is a treadmill that has to keep running faster. The 10-K is candid that the business is exposed to seasonality, changes in formulation and packaging, and competitor promotional programs "seasonality of our product offerings and (vi) the impact of changes in product formulation, packaging and advertising. We participate in the promotional programs o", the everyday pressures that erode a brand's position over time.

The valuation methods read the stock as value-supported, but the leverage is the qualifier. Net debt of roughly $0.9 billion runs above three times operating income on the report's basis, and the new acquisition debt lifts it further before cash flow brings it down. The company does not separately report interest expense in a way the report can turn into a coverage ratio, which leaves the leverage read less precise than ideal. The dividend-free, buyback-and-acquisition capital allocation is rational, but it competes with debt service for the same cash. The bear does not need the brands to collapse; it needs organic revenue to keep declining while the company adds leverage to paper over the gap, and a value multiple on a shrinking organic base is the classic shape of a slow trap.

Valuation

The price treats Prestige as a value-and-asset name rather than a growth story, which fits a brands portfolio with a declining organic top line. The methods broadly support the price: the asset-value, relative-multiple, and growth families all land at or above the quote, and the stock trades at a blended earnings multiple in the high teens against a consumer-health sector that commands more. The inversion frames the price as supported by the demonstrated economics, not as a bet on acceleration, which is the honest read of a 28%-margin business whose revenue slipped about 4% last year.

The peer-multiple lens is where the apparent cheapness shows most clearly. On both a P/E and an EV/EBITDA basis, the stock screens below the sector, with the relative methods landing well above the price, the market is paying less per dollar of earnings and EBITDA than comparable consumer-health names fetch. The earnings-power methods, which capitalize current cash flow, sit closer to the price, reflecting that the cash generation is strong but the growth credited to it is minimal. The disagreement is modest here; this is not a stock priced on a durability premium the static methods cannot frame, it is one priced near where the methods cluster, with the discount reflecting the organic-decline overhang.

Solvency is the load-bearing caveat. Net debt of about $0.9 billion runs above three times operating income on the report's basis, and the Breathe Right and LaCorium acquisitions are debt-financed, lifting leverage before the planned paydown. The company is not burning cash, free cash flow near $246 million comfortably covers debt service and the buyback, and the share count is falling. But the value case rests on the brands defending their economics while the leverage is worked down, and the recent organic decline is the variable that decides whether that paydown happens on schedule. The most decisive figure is organic revenue growth, because a value multiple on a portfolio that keeps shrinking organically is the difference between a bargain and a trap.

Catalysts

Prestige reported its fiscal 2026 results on May 13, 2026, and they missed expectations even as the year's earnings held. Full-year revenue was $1,088.7 million, down about 4%, with diluted earnings of $3.91 a share and adjusted earnings of $4.38. The fourth quarter was the weak point, revenue down 5% on lower eye-and-ear-care sales and Middle East shipping disruptions. The decline is the central fact the fiscal 2027 outlook has to reverse.

The acquisition news was the headline alongside the results. The company announced the purchase of Australia's LaCorium Health, a therapeutic skin-care business, for about $150 million, expected to close in the second quarter of fiscal 2027 and to add roughly $40 million of revenue and about $12 million of EBITDA including synergies. Separately, Prestige is acquiring the Breathe Right nasal-strip brand, a larger deal financed with new term loan debt that lifts near-term leverage.

Management introduced a fiscal 2027 outlook for organic revenue growth of 1% to 3%, framing a return to organic growth driven by recovering eye-care shipments and steady consumption, with volume expected to provide roughly two-thirds of the growth and pricing the rest. Analyst sentiment is buy-leaning but softening, with several recent price-target reductions even as ratings hold. The figures to watch are organic revenue growth and the pace of deleveraging once the Breathe Right and LaCorium debt is on the books.

Peer Cohorts (Per Segment, With Filing Citations)

North American OTC Healthcare (reported)

• HLN (Haleon plc)
• FY2025 20-F: …strategy has resulted in a portfolio more focused on higher-growth categories, markets and channels. These transactions also provided a catalyst for a broader transformation of the Group. Prior to its combination with the Novartis consumer healthcare business in 2015, GSK's consumer healthcare business was already…
• FY2025 20-F: …as reactive treatments, like antacids and laxatives. There is growing consumer demand for Digestive Health solutions, driven by increased awareness of the importance of gut health, as well as the increase in GLP-1 use1 . Our position Haleon is the #12 manufacturer in the global Digestive Health category, driven by…
• KVUE (Kenvue Inc.)
• FY2025 10-K: …at this stage, to assess reliably the outcome of these lawsuits or the potential financial impact on the Company. J&J has also received demands for indemnification for legal claims related to OTC Zantac products sold by third parties in the United States. In addition, our affiliate Johnson & Johnson Consumer Inc.,…
• FY2025 10-K: …the petition. In November 2025, a second citizen petition was filed by a third party, the Americans for Scientific Integrity, requesting the FDA update the labeling of OTC acetaminophen-containing drug products to reflect a potential risk of neurodevelopmental harm, including autism spectrum disorder, from exposure…
• PRGO (Perrigo Company plc)
• FY2025 10-K: …to the end of the period for which net sales are being measured. Notable new product launches in the year ended December 31, 2025 include Phenylephrine No Drip Nasal Spray, IBU/APAP Dual Active and the Trios TM program launch in CSCA and CSCI line extensions in the Bronchostop ® 5 in1 products, flavor roll outs in…
• FY2025 10-K: …primarily in Europe and Australia. During the first quarter of 2026, we have begun transitioning from a geographic segment reporting structure to a category-based segment view, enabling us to better align our financial disclosures and operational analysis with our product offerings and strategic priorities. The…
• CHD (CHURCH & DWIGHT CO., INC.)
• FY2025 10-K: …outside the United States, to distribute a medical device lawfully, we must demonstrate conformity to local or regional standards for quality, safety and performance. For class II medical devices, we must obtain either government approval or certification from an accredited and approved Notified Body ("NB") that also…
• FY2025 10-K: …by us, including TROJAN, NAIR, ORAJEL, WATERPIK, FIRST RESPONSE, XTRA, OXICLEAN, BATISTE, SIMPLY SALINE, ZICAM, THERABREATH, HERO and TOUCHLAND. Our portfolio of trademarks represents substantial value in the businesses using the trademarks. U.S. patents are currently granted for a term of 20 years from the date the…
• CLX (CLOROX CO /DE/)
• FY2025 10-K: …segment expenses regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. These amendments are to be applied retrospectively for all…
• FY2025 10-K: …2022-07-01 2023-06-30 0000021076 clx:CleaningMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2024-07-01 2025-06-30 0000021076 clx:CleaningMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-07-01 2024-06-30 0000021076…
• OGN (Organon & Co.)
• FY2025 10-K: …as of June 2, 2021, among Organon LLC, Organon Global Inc., Organon Trade LLC, Organon Pharma Holdings LLC, Organon USA LLC, Organon Canada Holdings LLC, each as guaranteeing subsidiary, Organon & Co., as issuer, Organon Foreign Debt Co-Issuer B.V ., as co-issuer and U.S. Bank National Association, as trustee and…
• FY2025 10-K: …that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 countries and territories. We sell these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers such as health…

International OTC Healthcare (reported)

• HLN (Haleon plc)
• FY2025 20-F: …strategy has resulted in a portfolio more focused on higher-growth categories, markets and channels. These transactions also provided a catalyst for a broader transformation of the Group. Prior to its combination with the Novartis consumer healthcare business in 2015, GSK's consumer healthcare business was already…
• FY2025 20-F: …as reactive treatments, like antacids and laxatives. There is growing consumer demand for Digestive Health solutions, driven by increased awareness of the importance of gut health, as well as the increase in GLP-1 use1 . Our position Haleon is the #12 manufacturer in the global Digestive Health category, driven by…
• KVUE (Kenvue Inc.)
• FY2025 10-K: …laws. For example, in November 2025, we received a non-public Civil Investigative Demand ("CID") from the Attorney General of the State of Texas pursuant to the Texas Deceptive Trade Practices-Consumer Protection Act. The CID seeks documents related to certain Aveeno ® Baby products that are labelled as…
• FY2025 10-K: …® Baby Powder. The claimants claim that the defendants are liable for negligence and the tort of deceit. Additionally, in February 2026, an Australian law firm announced it has commenced a proceeding in the Supreme Court of Australia against J&J and the Company's affiliates Johnson & Johnson Pty Ltd and Johnson &…
• PRGO (Perrigo Company plc)
• FY2025 10-K: …• Rx-to-OTC switches are part of our future growth. If regulatory agencies fail to approve Rx-to-OTC switches in new product categories or reassess the terms of existing OTC classifications, our growth prospects and product mix would be impaired. Further, regulatory agencies may reassess the terms of OTC…
• FY2025 10-K: …previously disclosed lost distribution of lower-margin products as the business focused on enhancing margin while balancing the unfavorable impacts of tariffs; • Skin Care: Net sales of $214.9 million decreased 2.4% due primarily to lower distribution of Minoxidil at one customer, partially offset by growth in the…
• CHD (CHURCH & DWIGHT CO., INC.)
• FY2025 10-K: …price/mix of $24.8, partially offset by the benefit of productivity programs of $89.1, higher sales volumes of $39.5, lower marketing expenses of $5.8, and lower SG&A expenses of $5.3. Consumer International 2025 compared to 2024 Consumer International net sales in 2025 were $1,129.4, an increase of $57.9 or 5.4% as…
• FY2025 10-K: IRST RESPONSE® home pregnancy and ovulation test kits; NAIR® depilatories; ORAJEL® oral analgesic; XTRA® laundry detergent; and ZICAM® cold shortening and relief products. Seven of those brands are designated as "power brands" because they compete in large categories, and we believe they have the potential for…
• OGN (Organon & Co.)
• FY2025 10-K: …ownership inclusive of risk of loss, market risk and benefits related to the inventory. Additionally, Organon has control in pricing, has the ability to direct Merck regarding decisions over inventory, and is responsible for all credit and collections risks and losses associated with the related receivables. As such,…
• FY2025 10-K: …60% for the year ended December 31, 2025, compared to 2024, due to sales ramp up since its launch in July 2023 in the United States and a modest increase in demand in Canada and Puerto Rico. We have commercialization rights to Hadlima in countries outside of the European Union, South Korea, China, Turkey, and Russia.…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.